Successful Batch Release in Japan: The Essential Guide

Important disclaimer

This article is a general primer. It is intended to give cross-functional teams a practical, high-level understanding of the preparation required to achieve successful batch release in Japan.

It is in no way a complete foundation on which any company should make regulatory, quality, manufacturing, supply-chain, investment or other business decisions. The applicable requirements and responsibilities depend on the product, approval, manufacturing sites, MAH structure, supply chain and agreements between the parties. Your company must obtain current, product-specific advice from appropriately qualified Japanese regulatory, legal and quality professionals before acting.

This article was written in September 2026. Laws, regulations, official guidance, administrative practice and industry expectations may have changed substantially by the time you read it. Always verify the current position with the relevant Japanese authorities and your responsible Japanese partners.

A pharmaceutical batch can be manufactured correctly, pass every analytical test and arrive in Japan on schedule. It can still remain in quarantine. In one real case, the problem was not the active substance, sterility, potency or temperature history. It was the smallest dent on the corner of a single secondary carton. In another: the labels on three checked syringes were leaning a few degrees , resulting in the batch release not happening that week.

From a distance, that may sound unreasonable. It is not. The Japanese organisation responsible for putting the product on the market could not simply decide that the damage did not matter. It had to determine whether the carton complied with the approved and agreed presentation, whether the defect was isolated, whether other cartons could have been affected, and whether the available inspection and documentation justified release. Same with the syringes. You can also frame the question: “If they cannot perform the simple task of placing labels perfectly, then WHAT ELSE do they have problems with?”

Any tiny defect will likely become a release problem.

⇒ This is the lesson: batch release in Japan begins long before the batch arrives in Japan.

Successful release is not a final signature added after manufacturing. It is the result of a connected system involving your quality, regulatory, manufacturing, packaging, logistics, document-control and commercial teams, together with your Japanese MA holder, manufacturers, laboratories, warehouse, importer and distribution partners.

If one part of that system is not ready, your product is probably not ready either.

First, understand what “batch release in Japan” means

People often speak about “PMDA batch release” as if the Pharmaceuticals and Medical Devices Agency reviews and approves every commercial batch. That is not an accurate description of the normal process.

PMDA and other competent Japanese authorities regulate the framework. Depending on the product and site, they review approvals, accredit foreign manufacturers and conduct GMP or GCTP compliance inspections. The Japanese MAH, carries responsibility for the product placed on the Japanese market and for the quality-management system supporting that activity.

Japan’s GQP requirements state that a pharmaceutical MAH must ensure that finished products are properly certified for market release or rejected. The MAH must not release the product before that certification has been suitably completed. The work is performed by the MAH’s Quality Assurance Manager (or designated qualified personnel within the MAH’s quality organisation) in Japan. Overseas finished-product manufacturers perform site release at their facilities under GMP, but cannot execute or have the statutory Japanese market release decision delegated. The MAH remains central to the system.

That is different from saying that a “Japanese Qualified Person” signs every batch in the same way as an EU QP. Do not build your Japanese procedure around familiar European terminology and assume that the responsibilities and workflows are the same.

The precise release route depends on:

• The type of product.
• The approved manufacturing and testing arrangements.
• The organisations and manufacturing sites named in the Japanese approval.
• The activities performed outside and inside Japan.
• The MAH’s quality-management procedures.
• The quality agreements between the parties.
• Product-specific testing, storage and distribution requirements.

Pharmaceuticals and most biologics are manufactured under the applicable Japanese GMP framework. Regenerative medical products, including relevant cellular and tissue-based products, are subject to GCTP manufacturing controls. Their logistics and release timelines may also be much less forgiving because of short shelf life, chain-of-identity requirements, cryogenic storage or patient-specific scheduling.

Guess who lives in the details!

Successful batch release in Japan is your full company’s undertaking

Quality assurance may own the procedure, but quality assurance cannot make the entire organisation release-ready on its own. Consider the many functions that can prevent a batch from reaching the Japanese market:

• Regulatory affairs may not have assessed a manufacturing or testing change against the Japanese approval.
• Manufacturing may close a deviation too late for the Japanese review timetable.
• QC may issue a certificate of analysis in a format that omits information required by the agreed release package.
• Packaging may use the correct artwork but apply variable information in the wrong position or format.
• Procurement may change a carton, label or shipping component without recognising its impact in Japan.
• IT issues may prevent the Japanese reviewer from accessing an electronic record.
• Logistics may use an unapproved route or fail to promptly recover temperature data.
• The warehouse may receive the goods without following the agreed quarantine and inspection protocols.
• The commercial team may decide a launch date without allowing time for receipt, sampling, testing, questions and final disposition.
• Senior management may assume that a batch already released globally is automatically ready for Japan.

Every one of these problems can ruin your batch release. The good news is they are all avoidable. Your company should therefore appoint one senior, accountable owner for Japan release readiness. That person does not need to perform every task. They must ensure that the complete system has owners, deadlines, evidence and escalation routes.

Map the entire release pathway first

Do not begin with a generic global standard operating procedure. Begin with the actual journey of your Japanese product. Put every step on one page, from the purchase and approval of packaging components to the moment saleable inventory becomes available in Japan. Include every organisation, physical movement, data transfer, review and decision. Your map should answer these questions:

• Who manufactures the active substance, intermediate and finished product?
• Who performs primary and secondary packaging?
• Which sites and activities are included in the Japanese marketing approval?
• Which laboratories perform release, import-related or other required testing?
• Who prepares each document?
• Who reviews it outside Japan?
• Who reviews it in Japan?
• Who may ask questions, and who must answer them?
• Who controls shipment, customs clearance, receipt and quarantine?
• Who performs incoming and visual inspection?
• Who makes or certifies the final release or rejection decision under the agreed Japanese procedure?
• How does the released stock move into commercial distribution?

For every step, record the required input, output, owner, backup owner and expected duration. Also record what happens when the step fails.

An arrow labelled “send documents to Japan” is not a process. Which documents? In what format? Through which system? How quickly? Who confirms completeness? What happens if a deviation remains open or a signature cannot be verified?

Such questions usually feel overly detailed … until your batch is not released.

Two example workflows from European manufacture to Japanese distribution

The following examples are deliberately simplified. They show how responsibilities and interfaces can be arranged, not the mandatory route for every product. The actual workflow must follow the product’s Japanese approval, applicable GMP or GCTP requirements, the MAH’s procedures and the agreements between the parties.

Workflow 1: The finished Japanese pack is manufactured and packed in Europe

In this example, a European site manufactures the product and completes the Japanese secondary packaging. The finished packs are imported into Japan in their intended market presentation.

Step 1: Manufacture and testing in Europe

The European manufacturing site produces the batch according to the process and sites included in the Japanese approval. The relevant laboratories complete the required testing against the applicable specifications.

Evidence created: Executed manufacturing records, laboratory results, certificate of analysis, environmental or process-monitoring records where applicable, and records of deviations, investigations and changes.

Common failure: A deviation is considered acceptable for Europe, but its relevance to the Japanese approval and release procedure had not been assessed, until it resulted in serious questions about the quality of your batch.

Step 2: Japanese packaging in Europe

The approved Japanese labels, cartons, leaflets and other components are applied at the authorised European packaging site. Variable information, including batch number and expiry date, is verified. Packaging reconciliation and visual inspection are completed against the agreed standards.

Evidence created: Packaging records, reconciliation, line-clearance records, artwork and component references, variable-data verification and inspection results.

Common failure: The artwork is technically correct, but a printing, placement, carton condition or pack configuration issue falls outside the rather narrow specifications your Japanese MAH has agreed to accept.

Step 3: Release from your European manufacturing site

The European site completes its own batch disposition and site-release responsibilities. If the product is also released for the European market, the applicable EU QP certification is completed separately. That European decision does not, by itself, constitute release to the Japanese market.

Evidence created: Site-release documentation, applicable certification and the agreed Japan release-document package.

Common failure: The foreign company assumes that an EU release automatically provides the Japanese MAH with everything required for Japan.

Step 4: Pre-shipment document review

Before physical shipment, the agreed batch documents are sent to the Japanese MAH or its designated quality team. The team checks completeness, identifies questions and confirms whether shipment may proceed under the agreed process.

This step prevents a batch from crossing the world only to wait for a document that could have been corrected in Europe.

Decision point: Is the package sufficiently complete to ship, recognising that final Japanese market release has not yet occurred?

Step 5: Shipment and importation into Japan

The finished packs are placed into the qualified shipping configuration and transported to Japan. Freight, customs, import documentation, temperature monitoring and handovers follow the agreed procedures.

Evidence created: Shipping records, customs and import records, seal information, temperature data and records of any delay or excursion.

Common failure: Temperature data cannot be downloaded promptly, a logger is missing, or visible transit damage has not been documented at the point of receipt.

Step 6: Receipt and quarantine in Japan

The Japanese warehouse confirms the shipment identity, condition, quantity and status. The goods remain segregated and under quarantine. Receipt inspection may identify damaged shipping cases, crushed corners, label problems or other discrepancies.

Decision point: Does the shipment match the expected product and arrive in a condition that allows the release process to continue?

Step 7: Japanese inspection and testing

The MAH ensures that the inspections, reviews and any testing required by the approved and agreed procedure are completed. Samples may be taken and sent to a designated laboratory where applicable. The exact testing model must be product-specific and should never be inferred from a generic workflow.

Evidence created: Receipt-inspection records, sampling records, laboratory results and investigation records for any discrepancies.

Common failure: The samples, reference standards, or documents required by the Japanese laboratory are unavailable upon shipment arrival.

Step 8: Japanese market-release decision

The Quality Assurance Manager (or designated QA representative) operating under the MAH’s GQP system reviews the required manufacturing, testing, packaging, transport, receipt and quality information. Questions and deviations must be resolved or formally assessed. The batch is then certified for release to the Japanese market or rejected under the approved procedure.

Decision point: Release or reject. Until this decision is properly completed and recorded, the stock does not become saleable Japanese inventory.

Step 9: Distribution in Japan

The warehouse status is changed from quarantine to released stock. The product can then move through the agreed Japanese distribution channel, which may include pharmaceutical wholesalers, hospitals, pharmacies or other authorised recipients.

The complete flow is:

European manufacture → European testing → Japanese packaging in Europe → European site release → pre-shipment review → shipment and import → Japanese quarantine → Japanese inspection and any required testing → MAH market release → Japanese distribution

This route can work well when the European packaging operation is mature, the Japanese presentation is stable, and the parties have a disciplined process for documentation and communication. Its weakness is distance. If the finished cartons arrive damaged or incorrectly presented, the available recovery options in Japan may be limited, slow and expensive.

Workflow 2: The product is manufactured in Europe and completed by a Japanese CDMO

In this example, the medicine or unlabeled finished product is manufactured in Europe. Japan-specific secondary packaging, inspection and other agreed activities are performed by a qualified Japanese CDMO. This can reduce the risk of transporting finished Japanese cartons over long distances and can make local correction, inspection or repacking more manageable.

Step 1: Manufacture and testing in Europe

The European manufacturer produces the bulk or finished dosage form in accordance with Japanese approval and the agreed process. The required European testing and manufacturing review are completed. For a biologic, this may mean filled vials or prefilled syringes awaiting secondary packaging in Japan. For another pharmaceutical, it may mean sealed primary packs. The permitted state at import depends on the approved supply chain.

Evidence created: Executed manufacturing records, analytical results, certificate of analysis, deviation and change information, and records supporting shipment.

Step 2: European site release for shipment

The European site confirms that the product can leave its control and provides the documentation required by the Japanese CDMO and MAH. The product is not yet released for sale in Japan.

Decision point: Is the product suitable for shipment to the Japanese manufacturing or packaging site for the next approved step?

Step 3: Qualified transport and importation

The product travels to Japan under the required temperature, security and status controls. Because the shipment may contain high-value unlabeled product, bulk material or temperature-sensitive biologics, identity, quantity, seals and chain of custody require particular attention.

Common failure: The physical shipment arrives, but the Japanese CDMO lacks an approved instruction, component, reference standard or complete document package needed to begin work.

Step 4: Receipt and quarantine at the Japanese CDMO

The CDMO receives the product into its quality system, verifies identity and condition, reconciles quantities and places the material under the correct status. Temperature data and shipping discrepancies are assessed.

Decision point: Can the imported material be accepted for the next manufacturing or packaging activity?

Step 5: Japan-specific testing or other local quality-control activities

The CDMO or an approved Japanese contract laboratory performs the testing and sampling assigned to it under the approval and quality agreements. For some products this step may be limited; for others it may be substantial. Methods, specifications, reference standards, sample quantities and data-transfer requirements must have been established in advance.

Evidence created: Sampling records, raw data, analytical results, method records and any deviation or investigation reports.

Step 6: Japanese secondary packaging

The Japanese CDMO applies the approved local label, carton, leaflet and other components. Variable information is printed and checked. Packaging reconciliation, line clearance and in-process controls are performed under the site’s quality system.

The Japanese presentation has therefore avoided the longest part of the international freight journey.

Evidence created: Executed packaging records, component reconciliation, variable-data verification and in-process control records.

Common failure: Headquarters changes global artwork or a primary component without giving the Japanese MAH and CDMO enough time to assess and implement the change.

Step 7: Local visual inspection and resolution of defects

The CDMO inspects the finished Japanese packs against the agreed defect standards. Because the product is already at an appropriately authorised Japanese site, the parties may have better access to controlled sorting, investigation, relabelling or repacking when approvals and procedures permit.

This does not mean that defects can be casually repaired. It means the recovery route may be shorter and governed through an established local quality system.

Step 8: CDMO review and release documentation

The CDMO reviews the work performed at its facility, resolves or escalates deviations, and completes its assigned site-release tasks in accordance with GMP/GCTP. The exact division between CDMO site release and MAH market release must be explicit in the quality agreement. Under the GQP framework, the CDMO certifies that manufacturing operations at its site conform to approved standards, while final authorisation to release the product to the Japanese commercial market remains the statutory duty of the MAH.

Common failure: Both parties assume the other is responsible for the final review of one document, deviation or test result.

Step 9: MAH oversight and Japanese market release

The MAH’s quality system ensures that the required release or rejection certification is properly completed and recorded. The MAH receives the necessary reports and maintains the oversight defined in its procedures and quality agreements.

Decision point: Release or reject the completed Japanese product.

Step 10: Distribution in Japan

Released stock moves from the CDMO or designated warehouse into the Japanese distribution network. Depending on the commercial arrangement, it may pass to a distributor or pharmaceutical wholesaler before reaching hospitals, pharmacies or treatment centres.

The complete flow is:

European manufacture → European testing and site release → controlled shipment of bulk or finished dosage form → Japanese CDMO quarantine → local testing where applicable → Japanese secondary packaging → local inspection → CDMO release activities → MAH market release → Japanese distribution

This route adds a Japanese manufacturing partner and requires careful technology transfer, qualification and governance. In return, it can remove several fragile cross-border interfaces and place packaging expertise, Japanese components, inspection and possible recovery activities closer to the market.

The decisive difference between the workflows

In the first workflow, Japan receives the completed market pack. This may appear simpler, but a packaging problem discovered after arrival can be very difficult to correct.

In the second workflow, Japan receives product that still requires authorised local activity. The operating model is more involved, but Japan-specific packaging and inspection occur close to the MAH and the market.

Neither workflow is automatically better. Compare them using total cost, release lead time, shipment risk, product stability, batch value, packaging complexity, available recovery routes, CDMO capability and the consequences of delay. For regenerative medical products, neither generic workflow should be copied without substantial adaptation. Autologous and other patient-specific products may require an order-to-treatment chain with individual identity, custody, scheduling and release controls rather than a conventional stock-to-wholesaler model.

Put the responsibilities into binding agreements

Japan’s GQP framework requires the MAH to establish agreements with relevant manufacturers covering matters including the scope of manufacturing activities, manufacturing and quality controls, release from manufacturing sites, technical requirements, transport and handover controls, audits, changes and the prompt communication of important quality information.

Your quality agreements must therefore describe the real operating model. They should not merely repeat that each party will “comply with applicable GMP.” At minimum, agree on:

• The activities performed by each party.
• The specifications and methods being applied.
• The content of the batch-release package.
• The procedure for release from each manufacturing site.
• The procedure for release to the Japanese market.
• Document formats, language and transmission method.
• Review periods and expected response times.
• Deviation, out-of-specification and investigation handling.
• Change notification and approval.
• Transport and handover controls.
• Complaints, quality defects and recalls.
• Audit rights and audit frequency.
• Data-integrity expectations.
• Record retention.
• Escalation contacts and decision authority.

The agreement should also cover the awkward cases. Who pays for sorting? Who can approve repacking? Where can relabelling be performed? Who investigates transit damage? What happens when only part of a shipment is affected? Who tells the commercial team that the planned release date is no longer credible? If the agreement is not completely thought through, the batch will wait while the companies negotiate under pressure.

Treat the Japanese presentation as part of product quality

The old and dangerous distinction is that the medicine is the “real product” and the carton is merely cosmetic.

The carton identifies, protects and communicates the product. Its artwork, printed information, components, condition and configuration form part of the presentation reviewed by the MAH and supplied to Japanese healthcare professionals and patients. A defect may be cosmetic, functional, regulatory or potentially misleading. You cannot decide which category applies by intuition alone.

This is why the dented-carton incident is so much more than a story to be told at cocktail parties.

The dent did not prove that the medicine was unsafe. It created uncertainty. Was it an isolated handling mark? Had the shipping case been compressed? Were other cartons damaged? Could the leaflet, label, tamper evidence or primary container have been affected? Did the defect meet an agreed classification? Was there an approved procedure for inspection and disposition?

If those questions have not been answered beforehand, even a tiny defect can stop release.

Before the first commercial packaging run, align on:

• The approved artwork and text.
• Fonts, symbols, colours and positioning.
• Lot and expiry printing.
• Barcodes and other variable data.
• Label placement and legibility.
• Tamper-evident features.
• Carton closure and orientation.
• Leaflets, trays, dividers and enclosed materials.
• Shipping-case and pallet configuration.
• Acceptable quality limits or other agreed sampling approach.
• Definitions and examples of critical, major and minor defects.
• Reference samples or an approved defect library.
• Inspection conditions and lighting where relevant.
• The authority to accept, reject, sort or investigate.

Photographs are useful, but a vague collection of pictures is not a defect standard. Provide examples, descriptions and agreed classifications. Train the people who will inspect the product. Test whether two inspectors classify the same defect in the same way.

Do not tell your Japanese partner that a defect “does not affect the drug.” Ask what evidence and procedure are needed to reach a documented disposition.

The perfectionist worldview behind Japanese batch release

There is also a Japanese worldview on quality that foreign teams need to understand.

It can feel like perfectionism because product quality is judged as a whole. The medicine, container, label, carton, leaflet, shipping conditions, documentation and the supplier’s behaviour all contribute to the assessment. A product is not divided neatly into “scientifically important” features and “merely cosmetic” details.

This does not mean that Japanese law requires every carton to be visually perfect. Nor does it mean that every Japanese MAH, customer or inspector will make the same decision about every small mark. Regulatory requirements, approved specifications, contractual requirements, defect standards and professional judgement must still govern the decision.

The practical difference is the significance given to a visible imperfection.

Many overseas teams see a small dent and ask:

Does this affect the safety, efficacy or pharmaceutical quality of the medicine?

The Japanese team usually also asks:

What allowed this defect to occur, what else might have happened, and what does it tell us about the supplier’s control of the complete product?

The dent therefore becomes more than a dent. It is a signal that the manufacturer may have poor quality control. And poor QC in pharma can kill patients.

If the supplier failed to protect one carton, was the shipping configuration properly tested? If one defect escaped inspection, are there others? If the supplier dismisses the defect without investigation, will it respond properly to a more serious problem? If the marketed pack is visibly damaged, what will the pharmacist, physician or patient infer about the product inside?

This is closely connected to trust. A Japanese MAH places its name, licence and reputation behind the product. The people making the release decision are not rewarded for accepting an unexplained deviation that later becomes a complaint. They need a controlled and defensible reason to release.

The resulting judgement can appear binary:

• The product matches the approved and agreed condition.
• Or it does not.

There is no category called “not quite right, but probably good enough.” Once a deviation has been identified, someone must classify it, determine its scope, assess its implications and document the disposition.

Foreign companies sometimes make the situation worse by calling this attitude irrational, excessively conservative or “only cosmetic.” That response attacks the judgement of the very people responsible for protecting the market. It also suggests that the supplier does not understand why consistency, presentation and reliable control matter.

A proper response is:

1. Understand the expected condition before production.
2. Agree on objective defect classifications and acceptance criteria.
3. Protect the product through packing, transport and receipt.
4. Investigate unexpected imperfections. Never become defensive or place blame elsewhere.
5. Give the responsible Japanese quality team the evidence needed to make a defensible decision.

You do not manage the perfectionist worldview by repeatedly asking your partner to tolerate imperfection. You manage it by removing ambiguity before the batch exists.

Build the release package before the batch exists

Many first batches are delayed because the product is complete, but the release package is not yet ready. Create a Japan-specific document inventory and review it with your MAH and other responsible partners. The exact content will vary, but here are some useful pointers:

• Executed batch manufacturing and packaging records.
• Certificates of analysis.
• Results against the approved specifications.
• Records from contract laboratories.
• Deviations and investigations affecting the batch.
• Out-of-specification or out-of-trend assessments.
• Change-control information.
• Environmental or process-monitoring records where applicable.
• Packaging reconciliation.
• Line-clearance and inspection records.
• Artwork and component approvals.
• Temperature and transport records.
• Shipping, import and receipt documentation.
• Evidence of storage and quarantine status.
• Sampling records.
• Required confirmations or attestations.
• Chain-of-identity and chain-of-custody records for patient-specific products.

Agree on what constitutes a complete record. A certificate saying “complies” may not be sufficient if the Japanese procedure requires actual results. A scanned signature may not be acceptable if authenticity cannot be established. A link to an electronic system is useless if the Japanese reviewer lacks access to it.

Check naming conventions, version control, dates, time zones, decimal notation, units and translations. These are small matters with a habit of becoming large matters at the wrong moment.

The release package should be assembled and challenged using representative documents before the commercial batch is manufactured.

Qualify the physical journey, not only the shipping container

A validated shipping solution is essential, particularly for biologics and regenerative medical products. It is not the whole supply chain. The product also passes through loading areas, airports, customs, freight forwarders, temporary storage, domestic transport, receiving docks, warehouses, sampling areas and sometimes external laboratories. Each handover creates another opportunity for delay, damage, temperature excursion or loss of status.

Map and qualify:

• Packing and pre-shipment inspection.
• Shipping-case closure and tamper controls.
• Palletisation and stacking limits.
• Data-loggers and access to their data.
• Courier and freight-forwarder responsibilities.
• Customs documentation and broker instructions.
• Contingency storage during delay.
• Receipt outside normal working hours.
• Japanese holiday and weekend coverage.
• Warehouse receipt, quarantine and segregation.
• Inspection and sampling.
• Movement to and from external laboratories.
• Return, sorting, repacking or destruction routes.

For regenerative medical products, the allowable time may be measured in hours rather than weeks. The trial must therefore test the actual timing, including flight schedules, customs availability, receipt capacity, product thawing or preparation, and coordination with the treatment site.

⇒ A temperature-controlled shipper does not solve a process that depends on one person opening an email sometime on Monday.

Run a mock release before the first commercial batch

A mock release is one of the least expensive ways to find expensive problems.

Do not limit the exercise to QA reviewing a blank template. Run the complete process with representative materials, realistic documents, the actual systems and the people who will perform the work.

For the exercise to be highly useful, test the following:

• Document generation at each manufacturing and testing site.
• Compilation of the complete Japan release package.
• Secure transmission and access permissions.
• Japanese review and query management.
• Translation where required.
• Signatures, dates and version control.
• Retrieval of temperature data.
• Warehouse receipt and quarantine status.
• Inspection against the agreed visual standards.
• Sampling and movement to the testing laboratory.
• Deviation notification and escalation.
• Release or rejection documentation.
• Transfer of status into the inventory and distribution systems.

Introduce realistic problems. Remove a document. Use an incorrect version. Add a small carton defect. Delay a temperature report. Make the normal approver unavailable. Test what happens.

Record every gap, its owner and its deadline. Repeat the critical parts after correction.

The output should not be “mock release completed.” It should be evidence that the organisation can release the product, together with a short list of remaining risks accepted by named decision-makers.

A successful trial gives you answers to questions that plans alone cannot settle:

• How long does the process actually take?
• Where do documents wait?
• Which questions are repeatedly misunderstood?
• Can the Japanese team access the source data?
• Are defect definitions interpreted consistently?
• Can deviations be escalated across time zones?
• Does the warehouse understand the product status?
• Can the commercial team see a credible release date?

One prevented launch delay will repay the entire preparation exercise many times over.

Communicate with your partners before there is a problem

Communication is not a courtesy added to the technical process. It is part of the control system. Your factory, product owner, MAH, CDMO, laboratory, logistics provider, warehouse and distributor do not naturally share the same systems or assumptions. Someone must create continuity between them.

Use a simple operating discipline:

1. Appoint one accountable release-readiness lead on each side.
2. Maintain one shared plan with owners and dates.
3. Hold regular cross-functional readiness meetings.
4. Record decisions, assumptions and unresolved questions.
5. Notify partners before making a relevant change.
6. Escalate uncertainty while there is still time to solve it.
7. Confirm important decisions in writing.
8. Explain the supply and launch consequences, not just the technical details.

Do not wait until the batch record arrives in Japan to reveal that a manufacturing deviation occurred. Do not ship and then ask whether the warehouse can receive on a national holiday. Do not assume that a packaging change accepted elsewhere is automatically acceptable for Japan.

Your Japanese partner should never be in for a negative surprise that you could reasonably have communicated earlier.

When something goes wrong

Even a well-prepared system will encounter deviations and defects. The objective is not to promise perfection. It is to respond without confusion.

A practical first response is:

1. Contain. Keep the affected product under the correct status and prevent unintended distribution.
2. Establish the scope. Determine which units, cases, pallets, documents or shipments may be affected.
3. Preserve evidence. Retain samples, photographs, logger data, records and packaging materials.
4. Notify. Inform the responsible quality personnel and other parties specified in the agreements.
5. Assess. Compare the facts with the approved requirements, specifications, procedures and agreed defect standards.
6. Investigate. Determine the cause and whether the issue could extend beyond what is immediately visible.
7. Decide. Release, reject, inspect, sort, retest, relabel or repackage only through an authorised and documented process.
8. Protect supply. Assess the effect on patients, launch, inventory and replenishment.
9. Prevent recurrence. Implement and verify the necessary corrective and preventive actions.

Two reactions are particularly dangerous.

1. The first is panic: treating every mark as proof that the complete batch is lost.
2. The second is dismissal: telling the Japanese partner that the defect is insignificant and expecting them to accept your opinion without an agreed standard, investigation or documented rationale.

The right response is controlled, evidence-based and F-A-S-T.

Your Japan batch-release readiness checklist

The complete checklist is available as a separate A4 PDF that your cross-functional team can print, complete and use during release-readiness meetings.

It covers eight connected areas:

1. Governance.
2. Regulatory and site readiness.
3. Agreements and procedures.
4. Product, packaging and artwork.
5. Release documentation and systems.
6. Logistics and receipt.
7. Mock release.
8. Launch and continuity.

It also provides space for named actions, owners, deadlines, critical open items and readiness sign-off.

[Download the Japan Batch-Release Readiness Checklist]

Use it for your early preparation. A tick should mean that the item has been confirmed with objective evidence, not merely discussed.

Weak answers do not necessarily mean that the batch cannot be manufactured. They show that the organisation is not yet ready to depend on successful release. You do not want to trust luck!

A Japanese CDMO can remove many of the interfaces

One strategic alternative is to use a capable CDMO in Japan for some or all of the late-stage manufacturing and supply activities.

Depending on its licences, facilities and agreed scope, a Japanese CDMO may perform:

• Secondary packaging and Japanese labelling.
• Procurement and control of local packaging components.
• Japan-specific testing or management of local laboratories.
• Storage and quarantine.
• Visual inspection.
• Sorting, relabelling or repacking through approved procedures.
• Preparation of documents for the Japanese quality system.
• Local deviation investigation.
• Coordination with the MAH, warehouse and distribution partners.

This reduces international handovers, freight exposure, communication delays and the practical difficulty of correcting a packaging problem after the product has arrived.

It can be particularly valuable for complex biologics and regenerative medical products, where the cost of delay is high and the time available for recovery may be too short to be realistic.

A CDMO does not eliminate your responsibilities. You still need to select and qualify the partner, define the scope, approve the agreements, manage changes, provide information and maintain oversight. Nor does the CDMO replace the Japanese MAH unless it separately holds and performs that role.

The benefit is not that you can stop caring about release. The benefit is that a well-chosen Japanese CDMO may already possess the people, procedures, facilities and local working relationships needed to manage activities that your company would otherwise have to build across several organisations.

The right question is therefore not simply, “Is manufacturing in Japan more expensive?”

Ask:

  ⇒ What is the total cost and risk of making every imported batch releasable, and where should the most failure-sensitive activities be performed?

Successful release is designed and rehearsed

Batch release in Japan is not achieved by sending a compliant batch and hoping that the remaining pieces will fall into place. It is achieved when:

• The approved product is manufactured and tested correctly.
• Every organisation understands its responsibility.
• The Japanese presentation has been defined and protected.
• The documents are complete, accessible and reviewable.
• The physical journey has been qualified.
• Problems are communicated before they become surprises.
• The complete process has been rehearsed.

That tiny dented corner is worth remembering. It shows how the smallest visible problem can expose a much larger weakness and create batch release risks and costs.

The objective is not to teach your team to fear Japan. Just look around you: There are already many companies who successfully operate in the Japanese market with long strings of successful batch releases. If they could achieve it, so can you! The goal is to build a system capable of assessing, communicating and resolving imperfections without losing control of the batch, the launch or the relationship with your Japanese partners.

Run the trial. Agree on the standards. Ask the awkward questions. Communicate early.

It is much cheaper to discover a gap while your batch is imaginary.

How Biosector can help

Biosector helps non-Japanese companies achieve commercial success within Japan’s pharmaceutical industry.

We do not perform regulatory submissions, act as your MAH or replace specialist quality and regulatory advisers. We help you understand the operating landscape, identify and assess suitable Japanese MAHs, CDMOs, laboratories, logistics providers and commercial partners, and create the relationships needed to make the Japanese undertaking work.

If you are planning your first commercial batch for Japan, bring us the pathway you currently expect to use. We will help you identify the missing participants, weak interfaces and practical questions that need answers before the product is waiting in quarantine.

You are warmly welcome to book a meeting with Biosector or email us at info@biosector.jp.

Primary references

• Pharmaceuticals and Medical Devices Agency, Ministerial Order on the Standard of Quality Management for Pharmaceuticals, Quasi-Pharmaceuticals, Cosmetics, and Regenerative Medicine Products. See particularly Articles 7 and 9 concerning agreements with manufacturers and control of product release to the market.
• Pharmaceuticals and Medical Devices Agency, Manufacturing and Marketing Procedures for Drugs, provisional translation as of August 2025.
• Pharmaceuticals and Medical Devices Agency, GMP Compliance Inspection concerning Drugs of Foreign Manufacturers.
• Pharmaceuticals and Medical Devices Agency, GMP, QMS and GCTP Inspections.
• Pharmaceuticals and Medical Devices Agency, Regenerative Medical Products.

Disclaimer:

This general primer was written in September 2026. It is not a complete basis for regulatory, quality, manufacturing, supply-chain, investment or other business decisions. Requirements and practices change and must be verified for the specific product and supply chain with the Japanese MAH, the relevant authorities and appropriately qualified Japanese regulatory, legal and quality professionals.